Hyperfine (NASDAQ:HYPR) Posts Earnings Results, Beats Estimates By $0.02 EPS

Key Points

• Hyperfine reported Q3 EPS of -$0.06, beating estimates by $0.02, and revenue of $5.96 million versus the $5.84 million consensus. Revenue rose 73% year over year to a record, while gross margin reached 56.7%.
• Operating loss narrowed to $7.3 million, and quarterly net cash burn fell 29% sequentially to $5.6 million. Hyperfine ended September with $37.9 million in cash and expects its runway to extend into 2028, assuming no additional financing or debt draws.
• Management maintained 2026 revenue guidance of $20 million–$22 million and cash-burn guidance of $26 million–$28 million, while raising the low end of its gross-margin outlook. It cited lumpy equipment sales and a one-time upgrade as reasons it did not raise revenue guidance.

Hyperfine (NASDAQ:HYPR - Get Free Report) announced its earnings results on Monday. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.02, FiscalAI reports. The business had revenue of $5.96 million for the quarter, compared to analysts' expectations of $5.84 million. Hyperfine had a negative return on equity of 97.88% and a negative net margin of 210.75%.

Here are the key takeaways from Hyperfine's conference call:

• Hyperfine reported a record $6.0 million in Q3 revenue, up 73% year over year, with contributions from U.S. hospitals, U.S. offices, and international markets. Gross margin reached a record 56.7%, and revenue grew much faster than operating expenses.
• Operating leverage improved: operating loss narrowed to $7.3 million, while net cash burn fell 29% sequentially to a quarterly low of $5.6 million—below quarterly revenue for the first time. The company ended September with $37.9 million in cash and expects runway into 2028, assuming no additional financing or future debt draws.
• Management reaffirmed 2026 revenue guidance of $20 million–$22 million and net cash burn guidance of $26 million–$28 million, while raising the low end of its gross-margin range to 52.5% from 50%. The revenue outlook was not raised despite the strong quarter; management cited the lumpy nature of capital-equipment sales and a one-time system upgrade that boosted Q4 2025 revenue.
• The company completed enrollment in its Contrast PMR study and remains on track to submit a 510(k) application by year-end 2026; management said clearance could come around Q2 to mid-2027. It expects contrast imaging to broaden use in hospitals and offices, including access to a dedicated reimbursement code in outpatient settings.
• Hyperfine is exploring a brain-health and wellness offering using its existing scanner, with potential software and cloud development rather than major hardware changes. Management characterized this as an emerging opportunity, but does not expect meaningful revenue from it before 2028 or later.

Hyperfine Trading Down 1.3%

HYPR traded down $0.01 during trading on Monday, hitting $0.71. The company's stock had a trading volume of 417,647 shares, compared to its average volume of 731,356. The firm has a market capitalization of $75.29 million, a P/E ratio of -1.87 and a beta of 1.49. Hyperfine has a twelve month low of $0.67 and a twelve month high of $1.94. The stock's fifty day moving average price is $0.80 and its 200-day moving average price is $1.11. The company has a quick ratio of 5.45, a current ratio of 6.15 and a debt-to-equity ratio of 0.36.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of Hyperfine in a research report on Thursday, October 15th. Wall Street Zen cut shares of Hyperfine from a "hold" rating to a "sell" rating in a research report on Sunday. Lucid Cap Mkts started coverage on shares of Hyperfine in a research note on Tuesday, October 27th. They set a "strong-buy" rating for the company. BTIG Research reissued a "buy" rating and set a $2.00 target price on shares of Hyperfine in a research note on Tuesday, September 22nd. Finally, B. Riley Financial restated a "buy" rating and issued a $1.60 target price (down from $2.00) on shares of Hyperfine in a report on Monday, August 10th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, Hyperfine presently has a consensus rating of "Moderate Buy" and a consensus price target of $2.02.

Hyperfine Company Profile

Hyperfine, Inc NASDAQ: HYPR is a medical technology company focused on making magnetic resonance imaging more accessible and convenient. The company develops portable, low-field MRI technology designed to bring brain imaging directly to patients in locations such as intensive care units, emergency departments, operating rooms and other point-of-care settings.

Hyperfine's primary product is the Swoop Portable MR Imaging System, a compact MRI platform that can be moved to a patient's bedside.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.